Good news! Weixin Kang Pediatric Multivitamins Injection (13) included in the National Health Insurance Catalogue

On the evening of January 18, 2023, the National Health Insurance Bureau and the Ministry of Human Resources Social Security issued the Notice on the Issuance of the National Drug Catalogue for Basic Medical Insurance, Work Injury Insurance and Maternity Insurance (2022)> (Health Insurance Fa [2023] No. 5), in which Tibet Weixinkang Pharmaceutical Co.,Ltd. (hereinafter referred to as "the Company") has been included in the 2022 edition of the National Health Insurance Catalogue through medical insurance negotiations. This version of the National Health Insurance Catalogue will be officially implemented from March 1, 2023. 

The Company's Pediatric Multivitamins For Injection（13）is a Multivitamin injection containing 13 vitamins, which is suitable for the prevention of vitamin deficiency in patients under 11 years of age receiving parenteral nutrition, and is the first generic and exclusive variety in China.

Pediatric Multivitamins For Injection（13） is a full-component parenteral vitamin preparation for pediatric use, which is in line with the dual standard prescriptions of China and the United States and the recommendations of authoritative guidelines at home and abroad, and is a key product of the Company's differentiated layout based on patient needs. The entry of the Pediatric Multivitamins For Injection（13） into the medical insurance catalogue will benefit more pediatric patients and more families.

With clinical needs as the guide, the company has always been based on research and development innovation, and now has a comprehensive layout in the pipeline of intravenous vitamins, trace elements, electrolytes and amino acid products for adults and children. In the future, the company will continue to live up to its corporate spirit of "responsibility, sharing, credibility and innovation" to care for the lives of the public and safeguard public health.